Combination Immunotherapy Targeting Sarcomas

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT04433221
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Ewing Sarcoma
  • Osteoid Sarcoma
  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
1 Year - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Multiple sarcoma-specific CAR-T cells and sarcoma vaccines — BIOLOGICAL
    1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection

Study Details

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.

Key Dates

First listed
Jun 16, 2020
Start date
Jul 1, 2026
Status verified
May 2026
Primary completion
May 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Multiple sarcoma-specific CAR-T cells
    Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers

Primary Outcome Measure

Safety of CART cells infusion [ Time Frame: 3 months ]

Central Contacts

Related Studies